Please login to the form below

Not currently logged in
Email:
Password:

Vimizim

This page shows the latest Vimizim news and features for those working in and with pharma, biotech and healthcare.

BioMarin prepares for haemophilia A gene therapy data readout, filing

BioMarin prepares for haemophilia A gene therapy data readout, filing

BioMarin already has six rare disease drugs already on the market, including its biggest earner Morquio syndrome treatment Vimizim, which reached $482m in revenues in 2018, up 17% and powering a

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Sales of the product will fit well into BioMarin's commercial infrastructure for its enzyme replacement therapies Naglazyme (galsulfase), for the treatment of Mucopolysaccharidosis VI, and Vimizim (elosulfase alfa) for Morquio

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Nektar Therapeutics appoints Jeff Ajer Nektar Therapeutics appoints Jeff Ajer

    officer. There he worked on establishing BioMarin’s global footprint and commercial infrastructure and has played a leadership role in the launches and growth strategies for brands including Brineura, Vimizim, Kuvan

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics